ArticleJournal of hepatocellular carcinoma2026
FOLFOX-HAIC Plus Lenvatinib and Tislelizumab in Advanced Hepatocellular Carcinoma with Arteriovenous Fistulae: A Real-World Study.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Patients with advanced hepatocellular carcinoma (HCC) complicated by arteriovenous fistula (AVF) often fail to benefit from conventional transarterial chemoembolization (TACE) because of the associated hemodynamic abnormalities, resulting in an extremely poor prognosis. This retrospective, single-center, single-arm study was conducted to preliminarily evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) using the FOLFOX regimen in combination with lenvatinib and tislelizumab in this population of patients with unresectable/advanced HCC. Methods: A total of 51 patients with advanced HCC complicated by angiographically confirmed AVF, who were treated at our institution between December 2020 and May 2025, were retrospectively enrolled. All patients received the aforementioned triple-therapy regimen as first-line treatment. The primary endpoint was progression-free survival (PFS), while secondary endpoints included overall survival (OS), objective response rate (ORR), fistula closure rate, and safety. Results: The median PFS and OS were 9.67 months and 14.63 months, respectively. According to the modified Response Evaluation Criteria in Solid Tumors (mRECIST), the ORR and disease control rate (DCR) were 72.55% and 92.16%, respectively. The overall AVF closure rate was 87.2%, and time-dependent covariate Cox regression analysis identified fistula closure as an independent protective factor for OS. Treatment-related adverse events (TRAEs) were manageable, and no treatment-related deaths occurred. Conclusion: This real-world study demonstrates that FOLFOX-based HAIC combined with lenvatinib and tislelizumab is associated with a high AVF closure rate, favorable survival outcomes, and a manageable safety profile in patients with unresectable/advanced HCC complicated by AVF. This combination regimen may offer a feasible therapeutic strategy for this refractory patient population; Meanwhile, we anticipate that prospective controlled studies will further consolidate and extend the current findings, so as to establish their clinical value in a more comprehensive manner.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.